Diridavumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | hemagglutinin |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number | 1393659-46-5 |
| ChemSpider | none |
| Chemical and physical data | |
| Formula | C6400H9934N1702O1996S48 |
| Molar mass | 144.2 kg/mol |
Diridavumab[1] is a monoclonal antibody designed for the treatment of influenza A.[2]
This drug was developed by Janssen Pharmaceutical Companies of Johnson & Johnson.
References
- ↑ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Diridavumab, American Medical Association.
This article is issued from Wikipedia - version of the 2/28/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.